News

Contract Pharma29m
Pfizer Inks $1.25 Billion Deal with 3SBio for Global Rights to Cancer Drug
Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.
Fierce Pharma13m
Fierce Pharma Asia—Pfizer's PD-1xVEGF bet; An Alzheimer's blood test approval; Samsung's biosim spinoff
Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...